PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
The purpose of this study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy
Breast Cancer
DRUG: PEG-rhG-CSF|DRUG: rhG-CSF
the occurrence rate of grade IV neutropenia during the first chemotherapy cycle, through first cycle of chemotherapy,an average of 1 month
the non-occurrence rate of grade IV neutropenia (ANC < 0.5 x 10^9/L)during the next three consecutive cycles chemotherapy(except the first chemotherapy cycle), through the next three consecutive cycles chemotherapy,an average of 3 months|the duration of grade IV neutropenia (ANC < 0.5 x 10^9/L) during the next three consecutive cycles chemotherapy(except the first chemotherapy cycle), through the next three consecutive cycles chemotherapy,an average of 3 months
The purpose of this study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy